"Could this help my depression? Could it make it worse?"

If you prescribe GLP-1 medications, expect to hear more questions like these. While early regulatory warnings linked the drugs to suicidal ideation, recent research suggests the opposite: GLP-1s may offer significant benefits for people with serious mental illnesses (SMI), including major depressive disorder, bipolar disorder, and schizophrenia.

"GLP-1s are fit for purpose in the contemporary management of people living with mental illness, and the way to think about it is twofold," said Roger McIntyre, MD, professor of psychiatry and pharmacology at the University of Toronto and lead author of a new study on GLP-1s and SMI mortality.

First, the drugs treat obesity, diabetes, and cardiovascular disease — all of which disproportionately affect people with SMI. Treating those conditions can improve overall quality of life and psychiatric outcomes.

Second is the question of direct action: Do GLP-1s themselves actively treat or prevent psychiatric symptoms?

"The way I respond to patients and families is: Stay tuned," McIntyre said. "Science is attempting to answer that question."

As GLP-1 prescriptions rise among patients with complex psychiatric histories, primary care providers and nurse practitioners are increasingly on the front lines. Communication with patients — and with other providers like psychiatrists— is crucial. Here's what clinicians need to know.

Three Research Takeaways to Share With Your Patients 

The short answer for patients: Safety data is solid, mental health effects are promising but preliminary, and there is a striking mortality benefit for patients with serious mental illness.

GLP-1s don't appear to harm mental health. Clinicians can offer clear reassurance to patients with or without preexisting psychiatric conditions. Substantial research shows that GLP-1 medications do not increase the risk for mental health issues or exacerbate existing ones.

A large systematic review and meta-analysis in JAMA Psychiatry found no link between GLP-1 treatment and serious psychiatric adverse events or worsening depressive symptoms, compared to placebo. In fact, GLP-1s were associated with modest improvements in quality of life.

"Family physicians, endocrinologists, and psychiatrists have no reason to be concerned about safety with these agents," said Mark Taylor, MD, a professor at Griffith University School of Medicine and Dentistry and co-author of two recent studies on GLP-1s and mental health. Taylor noted that his team also monitored for physical complications, such as pancreatitis and gallstones, and found no safety signals.

There may be direct psychiatric benefits. Clinicians should advise patients that while the science is promising — with much of the data centered on semaglutide — new evidence is still emerging. Just in the last few months, research has linked GLP-1 use to a lower risk for worsening mental illness and hospitalization for bipolar disorder— the two studies coauthored by Taylor — and substance use disorder. A paper in Translational Psychiatry further suggests that some mental health benefits may stem directly from the GLP-1 pathway itself, independent of weight loss. 

People with SMI live longer with GLP-1s. These drugs deliver profound cardiometabolic benefits to patients with severe psychiatric conditions. A retrospective study in JAMA Psychiatry co-authored by McIntyre — analyzing data from over 1.5 million matched adults — found that patients with SMI who started a GLP-1 had a 24% lower risk for dying from any cause over 4 years compared to those taking SGLT2 inhibitors, along with significantly lower rates of major adverse cardiovascular events.

"This is potentially transformative," McIntyre said. "For three decades, studies have consistently shown that people living with depression, bipolar disorder, or schizophrenia lose 10-25 years of potential life, largely driven by cardiovascular disease. Narrowing that egregious mortality gap is an urgent public health priority."

How to Help Patients Navigate GLP-1s and Mental Health

The evidence gives you room to have this conversation honestly — clarifying what the drug is and isn't, as well as how it fits into your patient's physical and mental healthcare. 

Position it as a physical intervention with potential spillover benefits. When working with a patient who has a serious mental illness, draw a clear boundary: GLP-1s are not a direct treatment for depression, bipolar disorder, or schizophrenia. But they bring about physical health improvements that can ultimately boost mood. 

"You still need to get treatment for your primary serious mental illness," said Marlene Hart, MD, board-certified in psychiatry and obesity medicine and the principal investigator at CenExel's clinical research center in Tampa, Florida. "Things may improve, you may feel better, but you won't be successful with the whole process if you don't stay stable on your psychiatric medicine."

Set realistic expectations beyond the scale. Many patients with SMI have struggled for years with weight gain caused by psychiatric medication. "They've been told, eat less, exercise more," Hart said. "[Now] these medications acknowledge it's a biological process." Some experience a dramatic and welcome reduction in food noise. Others find rapid appetite and weight changes emotionally complex; family and friends may not have a positive reaction to their reshaped body, or they may receive unwelcome attention from strangers. Reassure patients that these reactions are normal, and schedule regular check-ins to monitor them. On the physical side, emphasize long-term health benefits without overpromising. "It could not only make you healthier but could also perhaps reduce the impact that these conditions have on your lifespan," McIntyre said. 

Screen for stability, not just psychiatric history. An SMI diagnosis alone should not disqualify a patient; active psychiatric instability should. "I probably wouldn't initiate a GLP-1 when someone's had a crisis or recent changes in medications," Hart said. "They need to be at a point where they can focus on what they need to focus on." Before prescribing, confirm the patient is psychiatrically stable, engaged in ongoing care, and able to attend follow-up visits during titration.

Stay in touch with your patient's psychiatrist. Taylor's standard is low-friction but nonnegotiable: "As long as there's some written communication going between the different silos, that's all that matters," he said. At initiation, send a brief note outlining the GLP-1 plan, dosing schedule, and specific side effects the patient has been instructed to monitor. 

Strike the right clinical balance. Patients often see GLP-1s framed online as a panacea for everything from compulsions to mood disorders. Clinicians should temper expectations without dampening enthusiasm. "I don't regard it as a first-line treatment," Taylor said. "But if you've got issues with obesity or type 2 diabetes [alongside SMI], I think you've really got to think about adding a GLP-1 on top of your conventional psych treatment."

Ultimately, the answer to "Will this help or hurt?" is that the science is still unfolding — but your patients shouldn't have to wait for the final verdict to benefit today. 

Taylor has no relevant disclosures to report. 

McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, NeuraWell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eli Lilly, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, AbbVie, Bristol Myers Squibb, Teva, Adhere Tech, GH Research, Autobahn Therapeutics and Atai Life Sciences. 

Hart is a principal investigator at CenExel Tampa, a commercial research network that receives private industry funding.